

**Table EV1. Clinical characteristics of ALL patient samples**

sample	type	disease stage*	age [years]	sex	cytogenetics and gene fusions	mutations <sup>∞</sup>	Reference
ALL-1	ETP	ID	13	M	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-2	BCP	R	14	F	no BCR/ABL, no MLL/AF4, no TEL/AML1 t(9;14)	N.D.	-
ALL-3	ETP	ID	9	M	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-4	BCP	ID	1	F	TEL/AML1	N.D.	-
ALL-5	BCP	ID	2	M	TEL/AML1	N.D.	-
ALL-6	BCP	ID	1	F	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-7	BC-L	ID	20	M	N.D.	N.D.	-
ALL-8	DLBCL	CR	4	M	N.D.	N.D.	-
ALL-9	BCP	CR	3	M	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-10	BCP	CR	1	M	MLL del, AML1 gain, ABL gain	N.D.	-
ALL-11	BCP	R	8	M	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-12	BCP	R	2	F	no BCR/ABL, no MLL/AF4, no TEL/AML1	N.D.	-
ALL-50	BCP-ALL	ID	7	F	TCF3-PBX1; t(1;19)	N.D.	1

<b>ALL-177</b>	BCP-ALL	ID	8	F	ETV6-RUNX1; deletion 12p	N.D.	1,2
<b>ALL-199</b>	BCP-ALL	R2	8	F	somatic trisomy21; leukemic homozygous 9p deletion; P2RY8-CRLF2	N.D.	1,2
<b>ALL-230</b>	T-ALL	ID	4	M	t(11;14)(p32;q11); rearrangement of TAL1-gene with the T-cell receptor locus	NOTCH1	2
<b>ALL-233</b>	BCP-ALL	ID	<1	M	t(2;15)(p13;q15)	AKAP6, CSMD1, FAT1	2
<b>ALL-265</b>	BCP-ALL	R1	5	F	hyperdipoidy with additional 6,13,14,17,18,21,X chromosome	KMT2D, HERC1	1,2
<b>ALL-363</b>	BCP-ALL	ID	65	M	BCR-ABL p190; t(9;22)(q34,q11)	BCL11B, GRM3, IKZF1	2
<b>ALL-435</b>	BCP-ALL	ID	<1	M	MLL-ENL, t(11;19)	N.D.	2
<b>ALL-817</b>	BCP-ALL	ID	74	F	MLL-AF4; t(4;11)(q21;q23)	N.D.	-
<b>ALL-818</b>	BCP-ALL	ID	47	M	MLL-AF4; t(4;11)(q21;q23)	N.D.	-

\*when the primary sample was obtained; ∞ mutations determined by panel sequencing; BCP-ALL = B-cell precursor ALL; T-ALL = T-cell ALL; ETP = early T-cell precursor; DLBCL= diffuse large B-cell lymphoma; BC-L = B-cell leukemia; ID = initial diagnosis; R1 = 1<sup>st</sup> relapse; R2 = 2<sup>nd</sup> relapse; F = female; M = male; N.D. not determined.

<sup>1</sup> Heckl et al., Leuk Lymphoma 2019

<sup>2</sup> Ebinger et al., Cancer Cell 2016